Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/ki.2015.4 http://scihub22266oqcxt.onion/10.1038/ki.2015.4 C4490559!4490559!25671764     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kidney+Int 2015 ; 88 (1): 167-77 Nephropedia Template TP {{tp|p=25671764|t=2015. Current treatment practice and outcomes Report of the hyponatremia registry |pdf=|usr=}}{{25671764}} gab.com Text Current treatment practice and outcomes Report of the hyponatremia registry JO: Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=25671764 #FOAvip Current management practices for hyponatremia (HN) are incompletely understood. The HN Registry has recorded diagnostic measures, utilization, efficacy, and outcomes of therapy for eu- or hypervolemic HN. To better understand current practices, we analyzed data from 3087 adjudicated adult patients in the registry with serum sodium concentration of 130?mEq/l or less from 225 sites in the United States and European Union. Common initial monotherapy treatments were fluid restriction (35%), administration of isotonic (15%) or hypertonic saline (2%), and tolvaptan (5%); 17% received no active agent. Median (interquartile range) mEq/l serum sodium increases during the first day were as follows: no treatment, 1.0 (0.0?4.0); fluid restriction, 2.0 (0.0?4.0); isotonic saline, 3.0 (0.0?5.0); hypertonic saline, 5.0 (1.0?9.0); and tolvaptan, 4.0 (2.0?9.0). Adjusting for initial serum sodium concentration with logistic regression, the relative likelihoods for correction by 5?mEq/l or more (referent, fluid restriction) were 1.60 for hypertonic saline and 2.55 for tolvaptan. At discharge, serum sodium concentration was under 135?mEq/l in 78% of patients and 130?mEq/l or less in 49%. Overly rapid correction occurred in 7.9%. Thus, initial HN treatment often uses maneuvers of limited efficacy. Despite an association with poor outcomes and availability of effective therapy, most patients with HN are discharged from hospital still hyponatremic. Studies to assess short- and long-term benefits of correction of HN with effective therapies are needed. Twit Text FOAVip Current treatment practice and outcomes Report of the hyponatremia registry ????Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=25671764 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25671764 #FOAvip English Wikipedia <ref>{{Cite pmid|25671764}}</ref> Current treatment practice and outcomes Report of the hyponatremia registry #MMPMID25671764 Greenberg A; Verbalis JG; Amin AN; Burst VR; Chiodo III JA; Chiong JR; Dasta JF; Friend KE; Hauptman PJ; Peri A; Sigal SH Kidney Int 2015[Jul]; 88 (1): 167-77 PMID25671764show ga Current management practices for hyponatremia (HN) are incompletely understood. The HN Registry has recorded diagnostic measures, utilization, efficacy, and outcomes of therapy for eu- or hypervolemic HN. To better understand current practices, we analyzed data from 3087 adjudicated adult patients in the registry with serum sodium concentration of 130?mEq/l or less from 225 sites in the United States and European Union. Common initial monotherapy treatments were fluid restriction (35%), administration of isotonic (15%) or hypertonic saline (2%), and tolvaptan (5%); 17% received no active agent. Median (interquartile range) mEq/l serum sodium increases during the first day were as follows: no treatment, 1.0 (0.0?4.0); fluid restriction, 2.0 (0.0?4.0); isotonic saline, 3.0 (0.0?5.0); hypertonic saline, 5.0 (1.0?9.0); and tolvaptan, 4.0 (2.0?9.0). Adjusting for initial serum sodium concentration with logistic regression, the relative likelihoods for correction by 5?mEq/l or more (referent, fluid restriction) were 1.60 for hypertonic saline and 2.55 for tolvaptan. At discharge, serum sodium concentration was under 135?mEq/l in 78% of patients and 130?mEq/l or less in 49%. Overly rapid correction occurred in 7.9%. Thus, initial HN treatment often uses maneuvers of limited efficacy. Despite an association with poor outcomes and availability of effective therapy, most patients with HN are discharged from hospital still hyponatremic. Studies to assess short- and long-term benefits of correction of HN with effective therapies are needed. äCurrent treatment practice and outcomes Report of the hyponatremia re(epmc).pdf DeepDyve Pubget Overpricing